A5017521990- Colorectal Cancer Screening and Detection
- Genetic factors in colorectal cancer
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Epigenetics and DNA Methylation
- Pancreatic and Hepatic Oncology Research
- Esophageal Cancer Research and Treatment
- Inflammatory Bowel Disease
- Radiomics and Machine Learning in Medical Imaging
- Esophageal and GI Pathology
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Microscopic Colitis
- Cancer-related molecular mechanisms research
- Colorectal Cancer Treatments and Studies
- Diverticular Disease and Complications
- Mycobacterium research and diagnosis
- Eosinophilic Esophagitis
- Cancer-related gene regulation
- RNA modifications and cancer
- Colorectal Cancer Surgical Treatments
- Autoimmune and Inflammatory Disorders
- Colorectal and Anal Carcinomas
- Helicobacter pylori-related gastroenterology studies
- MicroRNA in disease regulation
- Gastrointestinal disorders and treatments
Mayo Clinic
2016-2025
WinnMed
2016-2025
Mayo Clinic in Arizona
2016-2025
University of Silesia in Katowice
2024
Mayo Clinic in Florida
2018-2024
Regenstrief Institute
2024
Indiana University Health
2024
Indiana University – Purdue University Indianapolis
2024
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
2024
Exact Sciences (United States)
2024
Early detection improves hepatocellular carcinoma (HCC) outcomes, but better noninvasive surveillance tools are needed. We aimed to identify and validate methylated DNA markers (MDMs) for HCC detection. Reduced representation bisulfite sequencing was performed on extracted from 18 35 control tissues. Candidate MDMs were confirmed by quantitative methylation‐specific PCR in independent tissues (74 HCC, 29 controls). A phase I plasma pilot incorporated allele‐specific real‐time target signal...
Colorectal adenomas are precursors of CRC. Recently, the gut microbiota, i.e., collection microbes residing in our gut, has been recognized as a key player CRC development. There have number microbiota profiling studies for colorectal adenoma and CRC; however, fewer considered metabolome, which serves chemical interface between host microbiota. Here, we conducted metabolome study analyzed metabolomic profiles together with paired composition profiles. We found several signatures that were...
A next-generation multitarget stool DNA test, including assessments of molecular markers and hemoglobin level, was developed to improve the performance colorectal cancer screening, primarily with regard specificity.
Discriminant markers for pancreatic cancer detection are needed. We sought to identify and validate methylated DNA using next-generation sequencing unbiased by known targets.
Hepatocellular carcinoma (HCC) can be treated effectively if detected at an early stage. Recommended surveillance strategies for at-risk patients include ultrasound with or without α-fetoprotein (AFP), but their sensitivity is suboptimal. We sought to develop a novel, blood-based biomarker panel improved early-stage HCC detection.In multicenter, case-control study, we collected blood specimens from and age-matched controls underlying liver disease HCC. Ten previously reported methylated DNA...
Abstract The multi-target stool DNA (mt-sDNA) test screens for colorectal cancer by analyzing methylation/mutation and hemoglobin markers to algorithmically derive a qualitative result. A new panel of highly discriminant candidate methylated (MDM) was recently developed. Performance the novel MDM panel, with hemoglobin, evaluated in simulated screening population using archived samples weighted early-stage prospectively collected advanced precancerous lesions (APL). Marker selection study...
<b>Background:</b> Anti-<i>Saccharomyces cerevisiae</i> antibodies (ASCA) are a specific but only moderately sensitive diagnostic marker for Crohn’s disease. We sought to explore the role of ASCA as prognostic aggressive disease phenotype in <b>Aims:</b> To determine status risk factor early surgery <b>Subjects:</b> performed case control study cohort patients, newly diagnosed with disease, between 1991 and 1999. All patients were followed at least three years. Case subjects (n = 35)...
Abstract BACKGROUND: Pancreatic cancer (PanC) presents at late stage with high mortality. Effective early detection methods are needed. Aberrantly methylated genes unexplored as markers for noninvasive by stool testing. The authors aimed to select discriminant and assess accuracy of these mutant KRAS in detect PanC. METHODS: Nine target were assayed real‐time methylation‐specific polymerase chain reaction (MSP) bisulfite‐treated DNA from microdissected frozen specimens 24 PanC cases 30...
Summary Background Chronic ulcerative colitis ( CUC ) and colonic Crohn's disease CD increase colorectal neoplasia CRN risk. While sessile serrated polyp SSP is a known cancer precursor, epithelial changes SEC are of uncertain prevalence neoplastic Aim To assess the lesion detection rates in documented incidence subsequent retrospective, single‐centre cohort study. Methods Patients were identified by central diagnostic index pathology review confirmed , diagnoses from 2006–12. Matched...
Extracellular vesicles (EVs) are of growing interest due to their potential diagnostic, disease surveillance, and therapeutic applications. While several studies have evaluated EV isolation methods in various biofluids, there few if any data on these techniques when applied stool. The latter is an ideal biospecimen for studying EVs colorectal cancer (CRC) because the release tumour markers by luminal exfoliation into stool occurs earlier than vascular invasion. Since a conserved mechanism,...
This cross-sectional study estimates the number of average-risk colorectal cancer screening–eligible individuals in US since Preventive Services Task Force updated its recommendations 2021.
BackgroundUlcerative colitis (UC) patients are at increased risk of colorectal dysplasia and cancer. Few studies have examined the clinical outcomes dysplastic polyps resembling sporadic adenomas that removed with endoscopic polypectomy.
Summary Background Current approaches to the detection of colorectal neoplasia associated with inflammatory bowel disease ( IBD ‐ CRN ) are suboptimal. Aim To test feasibility using stool assay exfoliated DNA markers detect . Methods This investigation comprised tissue and studies. In study, gene sequencing methylation assays were performed on candidate genes from 25 s mucosae without Mutations p53 , APC KRAS BRAF or PIK 3 CA insufficiently informative, but several aberrantly methylated...
Up to 30% of cases pouchitis are felt have a secondary cause. Cytomegalovirus (CMV) may represent possible etiopathological agent. Here, we report our experience with CMV involvement the pouch, including risk factors, clinical features, and pouch outcomes in patients inflammatory bowel disease after proctocolectomy ileal pouch-anal anastomosis.The pathology database at Mayo Clinic Rochester was searched between January 1995 October 2012 for tissue diagnosis following anastomosis.Seven...
Purpose: Gastric adenocarcinoma is the third most common cause of cancer mortality worldwide. Accurate and affordable noninvasive detection methods have potential value for screening surveillance. Herein, we identify novel methylated DNA markers (MDM) gastric adenocarcinoma, validate their discrimination in tissues from geographically separate cohorts, explore marker acquisition through oncogenic cascade, describe distributions candidate MDMs plasma cases normal controls.Experimental Design:...
Surveillance for hepatocellular carcinoma (HCC) has been recommended in patients with cirrhosis. In this study, we examined the extent to which competing risk of hepatic decompensation influences benefit HCC surveillance by investigating impact availability liver transplantation (LTx) and rate progression on survival gain from surveillance. A multistate Markov model was constructed simulating a cohort 50‐year‐old compensated The primary outcome interest all‐cause HCC‐specific mortality. main...
The burden of esophageal cancer continues to rise, and noninvasive screening tools are needed. Methylated DNA markers (MDM) assayed from plasma show promise in detection other cancers. For detection, we aimed discover validate MDMs tissue, determine their feasibility when plasma.